Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Go back to Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus| CARA THERAPEUTICS (NASDAQ: CARA) | Delayed: 5.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.32 | 52 Week High | $17.69 | |||
| Open | $5.32 | 52 Week Low | $4.26 | |||
| Day High | $5.32 | P/E | N/A | |||
| Day Low | $5.32 | EPS | $-0.42 | |||
| Volume | 215 | |||||
| FRESENIUS MEDICAL CARE AG & CO. KGAA (NYSE: FMS) | Delayed: 23.70 +0.31 (1.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.39 | 52 Week High | $47.52 | |||
| Open | $23.77 | 52 Week Low | $38.61 | |||
| Day High | $23.84 | P/E | N/A | |||
| Day Low | $23.61 | EPS | $0.00 | |||
| Volume | 490,977 | |||||
